Why do patients with metastatic breast cancer (MBC) continue to have bone destruction despite bisphosphonate (BP) use? A pathologic review

MLA

Ooi, W. S., et al. “Why Do Patients with Metastatic Breast Cancer (MBC) Continue to Have Bone Destruction despite Bisphosphonate (BP) Use? A Pathologic Review.” BONE, vol. 38, Mar. 2006, p. 81. EBSCOhost, https://doi.org/10.1016/j.bone.2006.01.044.

APA

Ooi, W. S., Gainford, C., Kahn, H., Kalina, M., Popovic, S., Singh, G., & Clemons, M. (2006). Why do patients with metastatic breast cancer (MBC) continue to have bone destruction despite bisphosphonate (BP) use? A pathologic review. BONE, 38, 81. https://doi.org/10.1016/j.bone.2006.01.044

Chicago

Ooi, W.S., C. Gainford, H. Kahn, M. Kalina, S. Popovic, G. Singh, and M. Clemons. 2006. “Why Do Patients with Metastatic Breast Cancer (MBC) Continue to Have Bone Destruction despite Bisphosphonate (BP) Use? A Pathologic Review.” BONE 38 (March): 81. doi:10.1016/j.bone.2006.01.044.